Literature DB >> 2466076

Induction of lysis by T cell receptor gamma delta+/CD3+ T lymphocytes via CD2 requires triggering via the T11.1 epitope only.

P S Goedegebuure1, D M Segal, E Braakman, R J Vreugdenhil, B A Van Krimpen, R J Van de Griend, R L Bolhuis.   

Abstract

The requirements for activation of the lytic machinery through CD2 of TCR gamma delta+/CD3+ cells were examined, by utilizing bispecific heteroconjugates containing anti-CD2 mAb cross-linked to anti-DNP. Contrary to the CD2 activation requirements in TCR alpha beta+/CD3+ cells, cytotoxic activity in TCR gamma delta+/CD3+ clones and TCR-/CD3- NK cell clones can be induced by heteroconjugates containing a single anti-CD2 (OKT11.1) mAb. Activation of TCR gamma delta+/CD3+ cells via CD2 is independent of heteroconjugates binding to CD16 (Fc gamma RIII), because heteroconjugates prepared from Fab fragments induced equal levels of lysis. Moreover, anti-CD16 mAb did not inhibit triggering via CD2 in TCR gamma delta+/CD3+ cells. In TCR-/CD3- NK cells, however, induction of cytotoxicity via CD2 is co-dependent on interplay with CD16. Anti-CD3 mAb blocked the anti-CD2 x anti-DNP heteroconjugate-induced cytotoxicity of TCR gamma delta+/CD3+ cells, indicating a functional linkage between CD2 and CD3 on these cells. We conclude that induction of lysis via CD2 shows qualitatively different activation requirements in TCR gamma delta+/CD3+, TCR alpha beta+/CD3+ CTL and TCR-/CD3- NK cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2466076

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

Review 2.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

Review 3.  Targeting of peripheral blood T lymphocytes.

Authors:  R L Bolhuis; H R Hoogenboom; J W Gratama
Journal:  Springer Semin Immunopathol       Date:  1996

Review 4.  T cell targeting in cancer therapy.

Authors:  R L Bolhuis; E Sturm; E Braakman
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Selective activation of gamma/delta + T cell clones by single anti-CD2 antibodies.

Authors:  S Wesselborg; O Janssen; K Pechhold; D Kabelitz
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

6.  Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis.

Authors:  P Fisch; M Malkovsky; E Braakman; E Sturm; R L Bolhuis; A Prieve; J A Sosman; V A Lam; P M Sondel
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

7.  Signal transduction by the CD2 antigen in T cells and natural killer cells: requirement for expression of a functional T cell receptor or binding of antibody Fc to the Fc receptor, Fc gamma RIIIA (CD16).

Authors:  L L Spruyt; M J Glennie; A D Beyers; A F Williams
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.